5‐azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors
Abstract (Source: The Prostate)div id=medwormpbiMedWorm Message:/i/b Please support the a href=http://www.doctorsinchains.org/ target=_blankDoctors In Chains/a campaign for the a href=http://www.doctorsinchains.org/medics/a tortured and sentenced for up to 15 years in a href=http://www.doctorsinchains.org/Bahrain/a. a href=https://twitter.com/#!/search/%23FreeDoctors#FreeDoctors/a/p/div

Cost‐effectiveness analysis of degarelix for advanced hormone‐dependent prostate cancer
CONCLUSION• Degarelix is unlikely to be cost‐effective compared to triptorelin plus short‐term antiandrogen in the management of advanced prostate cancer with respect to the usual thresholds of cost‐effectiveness used in the UK: £20 000–30 000 per QALY gained (used by the National Institute for Health and Clinical Excellence). (Source: BJU International)